Sunday, July 13, 2014





FDA approves Celgene drug for pancreatic cancer


September 06. 2013 7:40PM
Associated Press

Story Tools
PrintPrint | E-MailEMail | SaveSave | Hear Generate QR Code QR
Send to Kindle


(AP) Federal regulators have approved Celgene Inc.'s drug Abraxane to treat late-stage pancreatic cancer.


In experimental trials, the drug extended the lives of patients by a little less than two months more than those treated with the current standard drug.


Abraxane is already approved to treat breast cancer and a type of lung cancer. It accounted for $155 million in revenue for Celgene in the second quarter.


Pancreatic cancer is considered especially deadly and hard to treat. It typically causes few symptoms until it has spread enough that it can't be surgically removed.


The National Cancer Institute estimates about 45,000 patients will be diagnosed and about 38,000 will die from the disease this year.


Associated Press


Comments
comments powered by Disqus Commenting Guidelines
Poll
Mortgage Minute


Search for New & Used Cars

Make 
Model
 
Used New All
 

Search Times Leader Classifieds to find just the home you want!

Search Times Leader Classifieds to find just what you need!

Search Pet Classifieds
Dogs Cats Other Animals



Social Media/RSS
Times Leader on Twitter
Times Leader on Youtube
Times Leader on Google+
The Times Leader on Tumblr
The Times Leader on Pinterest
Times Leader RSS Feeds